LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

LLY

805.71

-1.45%↓

UNH

556.95

-1.68%↓

JNJ

158.12

-1.16%↓

NVO

109.92

-1.81%↓

ABBV

200.71

-1.24%↓

Home・Listă Acțiuni・Chimerix Inc

Chimerix Inc

Deschisă

Sector Sănătate

0.97

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

0.95

Maxim

1.04

Indicatori cheie
By Trading Economics
Vânzări	4K
EPS	-0.2
Angajați	72

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+627.27 upside

Dividende
By Dow Jones
Următoarele câștiguri	7 nov. 2024

Statistici piață
By TradingEconomics
Capitalizare de piață	-3.6M 88M
Deschiderea anterioară	0.97
Închiderea anterioară	0.97

Sentimentul știrilor

By Acuity

16%

84%

29 / 390 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Strong Bullish Evidence

0.78 / 0.843 Suport & Rezistență

Chimerix Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

3 nov. 2024, 23:05 UTC

Top știri

Fitch Affirms Australia's Sovereign AAA Rating, But Warns Of Mounting Budget Risks

3 nov. 2024, 21:12 UTC

Câștiguri

Westpac Says Annual Profit Falls 3%, Upbeat on Prospects -- Update

3 nov. 2024, 20:59 UTC

Câștiguri

Westpac Says Annual Profit Falls 3%, Upbeat on Prospects

3 nov. 2024, 23:34 UTC

Top știri

Stocks Poised for Lower Open -- Barrons.com

3 nov. 2024, 23:16 UTC

Top știri

Câștiguri

Berkshire Hathway Earnings Weren't as Bad as They Looked -- Barrons.com

3 nov. 2024, 22:50 UTC

Achiziții, Fuziuni, Preluări

Santos Says Working Interest in PNG LNG Now 39.9%

3 nov. 2024, 22:50 UTC

Achiziții, Fuziuni, Preluări

Santos Says Kumul to Assume $90 Million of Project Finance Debt Associated With Stake

3 nov. 2024, 22:49 UTC

Achiziții, Fuziuni, Preluări

Santos Says Final Payment Takes Total Cash Consideration to $602 Million

3 nov. 2024, 22:49 UTC

Achiziții, Fuziuni, Preluări

Santos Receives Final $241 Million Payment From Kumul

3 nov. 2024, 22:48 UTC

Achiziții, Fuziuni, Preluări

Santos Completes Sale of 2.6% Interest in PNG LNG to Kumul Petroleum

3 nov. 2024, 20:37 UTC

Câștiguri

Westpac FY 2024 Deposits Increased 5% to A$674 Billion

3 nov. 2024, 20:37 UTC

Câștiguri

Westpac FY 2024 Loans Increased 4% to A$807 Billion

3 nov. 2024, 20:37 UTC

Câștiguri

Westpac FY 2024 Impairment Charges 7 Bps of Loans

3 nov. 2024, 20:37 UTC

Câștiguri

Westpac FY 2024 Operating Expenses A$10.94 Billion, Up 7% Excluding Notable Items

3 nov. 2024, 20:36 UTC

Câștiguri

Westpac FY 2024 Non-Interest Income A$2.84 Billion, Down 15%

3 nov. 2024, 20:35 UTC

Câștiguri

Westpac FY 2024 CET1 Level 2 Capital Ratio 12.5%, Up 11 Bps

3 nov. 2024, 20:35 UTC

Câștiguri

Westpac Raises Share Buyback Program by A$1 Billion

3 nov. 2024, 20:35 UTC

Câștiguri

Westpac Final Dividend A$0.76/Share

3 nov. 2024, 20:33 UTC

Câștiguri

Westpac FY 2024 Net Interest Margin Down 1 Bps at 1.95%

3 nov. 2024, 20:32 UTC

Câștiguri

Westpac FY 2024 Revenue A$21.59 Billion, Flat on FY 2023

3 nov. 2024, 20:32 UTC

Câștiguri

Westpac FY Net Profit A$6.99 Billion, Down 3%

3 nov. 2024, 18:09 UTC

Top știri

Boeing Had a Big Week. This One Is Even Bigger. -- Barrons.com

3 nov. 2024, 10:30 UTC

Top știri

Fed Prepares Rate Cut Amid Economic Contradictions -- WSJ

3 nov. 2024, 03:00 UTC

Top știri

Disgraced Lebanese Central Banker Who Was a Fugitive Now Awaits His Fate -- WSJ

2 nov. 2024, 13:53 UTC

Top știri

Câștiguri

Achiziții, Fuziuni, Preluări

Warren Buffett's Berkshire Hathaway Slashes Apple Stake Again -- Update

2 nov. 2024, 13:44 UTC

Câștiguri

Achiziții, Fuziuni, Preluări

Berkshire Sold 25% of Its Apple Stock in the Third Quarter -- Barrons.com

2 nov. 2024, 13:00 UTC

Top știri

China's EV Makers Set Sights on Latin America in Global Expansion -- WSJ

2 nov. 2024, 12:58 UTC

Câștiguri

Achiziții, Fuziuni, Preluări

Berkshire Sold 25% of Its Apple Stock in the Third Quarter -- Barrons.com

2 nov. 2024, 12:48 UTC

Top știri

Câștiguri

Achiziții, Fuziuni, Preluări

Warren Buffett's Berkshire Hathaway Slashes Apple Stake Again -- WSJ

2 nov. 2024, 12:32 UTC

Câștiguri

Berkshire Profits Fell 6% in Third Quarter. The Buybacks Are on Pause. -- Barrons.com

Comparație

Modificare preț

Chimerix Inc Așteptări

Obiectiv de preț

By TipRanks

627.27% sus

Prognoză pe 12 luni

Medie 7.2 USD 627.27%

Maxim 11 USD

Minim 5 USD

În baza a 5 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruChimerix Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

5 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 5 analiști care au acordat evaluări ale acțiunilor Chimerix Inc - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

0.78 / 0.843Suport & Rezistență

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

29 / 390 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

EBITDA

Profit operațional

Despre Chimerix Inc

Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. The Company has two clinical-stage product candidates, dociparstat sodium (DSTAT) and brincidofovir (BCV). DSTAT is a heparin derivative that enables dosing at higher concentrations to achieve anti-inflammatory. DSTAT is in development as a potential first-line therapy in acute myeloid leukemia (AML) and as a potential treatment for acute lung injury (ALI) in Coronavirus disease 2019 (COVID-19) patients. BCV is an investigational lipid conjugate that is in development as a medical countermeasure for smallpox. The Company’s other pipeline candidates include ONC201, ONC206, ONC206 and ONC212.